Teladoc Stock Drops 25.96% Monthly as Q4 EPS Forecast at -$0.19
Teladoc closed at $4.56, down 1.94% on the day and off 25.96% over the past month, underperforming the Medical Services sector’s 0.31% gain and the S&P 500’s 1.43% loss. Analysts project its fourth-quarter EPS at -$0.19, up 32.14% year-over-year, on revenues of $633.91 million, down 1.03% from last year’s quarter.
1. Daily and Monthly Stock Performance
Teladoc shares ended trading at $4.56, a 1.94% decrease from the prior session. Over the last month, the stock has slipped 25.96%, trailing the Medical Services sector’s 0.31% advance, the S&P 500’s 1.43% decline, the Dow’s 0.07% gain and the Nasdaq’s 0.14% rise.
2. Q4 Earnings and Revenue Projections
The company’s fourth-quarter earnings per share are projected at -$0.19, representing a 32.14% improvement versus the same quarter a year ago. Revenue is expected to reach $633.91 million, a 1.03% decline from the prior-year period, with results due on February 25, 2026.
3. Analyst Rating and Industry Position
Consensus estimates place Teladoc at a Hold rating with no recent EPS revisions. The Medical Services industry ranks 144th out of over 250 industries, positioning it in the bottom 42% and highlighting sector-wide headwinds.